Sabatolimab
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells[1].
Product Specifications
CAS Number
[2252262-24-9]
Product Name Alternative
MBG453
UNSPSC
12352203
Target
Tim3
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/sabatolimab.html
Purity
99.15
Solubility
H2O
Smiles
[Sabatolimab]
Molecular Weight
(144.675 kDa)
References & Citations
[1]Andrew M. Brunner, et al. Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) : Updated Results from a Phase 1b Study. Blood (2020) 136 (Supplement 1) : 1–2.|[2]Schwartz S, et al., Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor. Immunother Adv. 2022 Aug 10;2 (1) :ltac019.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MP0286F Each
Magic™ Antibody Discovery - Human IgG3 (99-377) Membrane Protein, PaRoom Temperatureial
Ask
View Details